Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)

Summary

The clinical study with UMC119-06 is designed to investigate the safety in patients with moderate acute respiratory distress syndrome ("ARDS"). This will be a dose escalation, open-label, single-center study in adult with ARDS. UMC119-06 is ex vivo cultured human umbilical cord derived mensenchymal stem cells (hUC-MSCs) product which is intended for treatment of ARDS.

Timeline

Start

2024-01-01

Primary completion

2024-09

Completion

2025-09

Drugs

Indications